Assignee
IGNYTA INC
US·27 granted patents·12 pending applications·145 citations·filing 2013–2021
Top patents by PatentIndex Score
39 records- 0197US9149464B2Bendamustine derivatives and methods of using sameIGNYTA INC·Filed 2015·Granted Oct 6, 2015·40 cites·19 claims
- 0297US9150517B2Bendamustine derivatives and methods of using sameIGNYTA INC·Filed 2015·Granted Oct 6, 2015·40 cites·2 claims
- 0393US9120778B2Uracil derivatives as AXL and c-MET kinase inhibitorsIGNYTA INC·Filed 2015·Granted Sep 1, 2015·5 cites·11 claims
- 0493US9029538B2Uracil derivatives as AXL and c-MET kinase inhibitorsIGNYTA INC·Filed 2014·Granted May 12, 2015·8 cites·19 claims
- 0590US9522902B2Uracil derivatives as AXL and c-MET kinase inhibitorsIGNYTA INC·Filed 2015·Granted Dec 20, 2016·4 cites·15 claims
- 0687US10231965B2Molecules for administration to ROS1 mutant cancer cellsIGNYTA INC·Filed 2015·Granted Mar 19, 2019·7 cites·20 claims
- 0787US9452988B2Bendamustine derivatives and methods of using sameIGNYTA INC·Filed 2013·Granted Sep 27, 2016·3 cites·25 claims
- 0885US10085979B2Combinations for the treatment of neuroblastomaIGNYTA INC·Filed 2015·Granted Oct 2, 2018·7 cites·8 claims
- 0985US9718810B2Solid state forms of a quinazoline derivative and its use as a BRAF inhibitorIGNYTA INC·Filed 2016·Granted Aug 1, 2017·2 cites·15 claims
- 1085US9353097B2Solid state forms of a quinazoline derivative and its use as a BRAF inhibitorIGNYTA INC·Filed 2015·Granted May 31, 2016·3 cites·12 claims
- 1184US10398693B2Pharmaceutical compositions and dosage formsIGNYTA INC·Filed 2018·Granted Sep 3, 2019·4 cites·25 claims
- 1283US10682348B2Molecules for administration to ROS1 mutant cancer cellsIGNYTA INC·Filed 2019·Granted Jun 16, 2020·1 cites·10 claims
- 1382US10561651B2Methods for treating neuroblastomaIGNYTA INC·Filed 2018·Granted Feb 18, 2020·3 cites·8 claims
- 1482US10357490B2Combinations for the treatment of neuroblastomaIGNYTA INC·Filed 2018·Granted Jul 23, 2019·4 cites·20 claims
- 1582US9914730B2Azaquinazoline inhibitors of Atypical protein Kinase CIGNYTA INC·Filed 2013·Granted Mar 13, 2018·6 cites·13 claims
- 1682US9896446B2Azaquinazoline inhibitors of atypical protein kinase CIGNYTA INC·Filed 2015·Granted Feb 20, 2018·4 cites·14 claims
- 1777US10869864B2Combinations for the treatment of cancerIGNYTA INC·Filed 2016·Granted Dec 22, 2020·1 cites·15 claims
- 1877US10028956B2Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agentsIGNYTA INC·Filed 2014·Granted Jul 24, 2018·2 cites·8 claims
- 1971US11007191B2Pharmaceutical compositions and dosage formsIGNYTA INC·Filed 2020·Granted May 18, 2021·1 cites·20 claims
- 2070US2018147186A1Bendamustine derivatives and methods of using sameIGNYTA INC·Filed 2018·Application pending·0 cites
- 2167US10017496B2Uracil derivatives as AXL and c-MET kinase inhibitorsIGNYTA INC·Filed 2017·Granted Jul 10, 2018·0 cites·2 claims
- 2266US9913827B2Bendamustine derivatives and methods of using sameIGNYTA INC·Filed 2017·Granted Mar 13, 2018·0 cites·20 claims
- 2365US9987281B2Solid state forms of a quinazoline derivative and its use as a BRAF inhibitorIGNYTA INC·Filed 2017·Granted Jun 5, 2018·0 cites·20 claims
- 2464US9914731B2Pyrazolo[1,5-a]pyridine derivatives and methods of their useIGNYTA INC·Filed 2014·Granted Mar 13, 2018·0 cites·18 claims
- 2564US2021322439A1Compositions and methods for treating patients with rtk mutant cellsIGNYTA INC·Filed 2021·Application pending·0 cites
- 2664US2016016912A1Bendamustine derivatives and methods of using sameIGNYTA INC·Filed 2015·Application pending·0 cites
- 2763US9630926B2Bendamustine derivatives and methods of using sameIGNYTA INC·Filed 2016·Granted Apr 25, 2017·0 cites·18 claims
- 2862US9745283B2Uracil derivatives as AXL and c-MET kinase inhibitorsIGNYTA INC·Filed 2016·Granted Aug 29, 2017·0 cites·29 claims
- 2960US2021113555A1Combinations for the treatment of cancerIGNYTA INC·Filed 2020·Application pending·0 cites
- 3057US11253515B2Pharmaceutical compositions and dosage formsIGNYTA INC·Filed 2020·Granted Feb 22, 2022·0 cites·22 claims
- 3156US2018148447A1Pyrazolo[1,5-a]pyridine derivatives and methods of their useIGNYTA INC·Filed 2018·Application pending·0 cites
- 3248US2017007599A1Methods for treating neuroblastomaIGNYTA INC·Filed 2015·Application pending·0 cites
- 3345US2019151317A1METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTSIGNYTA INC·Filed 2018·Application pending·0 cites
- 3444US2018177792A1Compositions and methods for treating patients with rtk mutant cellsIGNYTA INC·Filed 2016·Application pending·0 cites
- 3542US2018256570A1Topical formulationsIGNYTA INC·Filed 2016·Application pending·0 cites
- 3641US2017356918A1Multiplexed immunohistochemistry assays for diagnosis and treatment of cancerIGNYTA INC·Filed 2015·Application pending·0 cites
- 3735US2019185567A1Combinations for the treatment of cancerIGNYTA INC·Filed 2017·Application pending·0 cites
- 3835US2019224200A1Combinations for the treatment of cancerIGNYTA INC·Filed 2017·Application pending·0 cites
- 3933US10799503B2Methods for the treatment of cancerIGNYTA INC·Filed 2017·Granted Oct 13, 2020·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when IGNYTA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →